Effect of Nitric Acid Oxidation on Vapor Grown Carbon Fibers (VGCFs). Use of these Fibers in Epoxy Composites

Pyrograf IIITM,/sup\u3e fibers (PR-19-PS, Applied Sciences, Inc.) with 100-300 nm diameters and ~ 10-100 ìm lengths were used with a low viscosity aliphatic epoxy resin (Clearstream 9000, Clearstream Products, Inc.) to produce composites. The VGCFs were oxidized in 69-71 wt% nitric acid (115°C) for various times (10 min to 24 h) to modify the surface to enhance fiber/matrix adhesion. Remarkably, little fiber weight loss was detected even after 24 h of oxidation. Composites containing 19.2 volume percent (29.4 weight percent) VGCFs were prepared. Their flexural strengths and flexural moduli were obtained. The flexural strengths did not increase using oxidized VGCFs. Fiber surfaces were characterized using N2 BET, CO2 DR, XPS, SEM, TEM and base uptake measurements. Increasing the oxidation time produced only small initial increases in surface area up to a limit. Significant surface oxygen was present before oxidation and the amount increased initially, though not continuously, with nitric acid oxidation

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)